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ABSTRACT

OmiHtrA2 is a highly conserved mammalian serine protease that belongs to the HtrA
family of proteins. Omi shares homology with the bacterially expressed heat shock protease
HtrA, which functions as a protease at higher temperatures and a chaperone at lower
temperatures. Additionally, Omi shares sequence similarity with the mammalian homologs
L56/HtrA1 and PRSP/HtrA3. Omi was first isolated as an interacting protein of Mxi2, an
alternatively spliced form of the p38 stress-activated kinase, using a modified yeast two-hybrid
system. Omi localizes in the mitochondria and in response to apoptotic stimuli the mature form
of this protein translocates to the cytoplasm.

In the cytoplasm Omi participates in both the

caspase-dependent as well as caspase-independent apoptosis.

Additionally, recent studies

suggest that Omi may have another unique function, maintaining mitochondrial homeostasis
within the mitochondria. In an effort to further elucidate the function of Omi, a yeast two-hybrid
screening was performed to isolate novel interacting proteins. This screening identified a novel
protein (HOPS), as a specific interactor of Omi. The predicted amino acid sequence of this
protein does not provide any information about its potential function in mammalian cells.
However, experiments show that HOPS is cleaved in vitro by Omi. Furthermore, in response to
apoptotic stimuli, HOPS is also degraded in vivo. This study suggests that HOPS could be a
physiological substrate of Omi that is cleaved and removed during apoptosis.
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CHAPTER ONE: INTRODUCTION AND REVIEW OF LITERATURE

1.1 Cell Death-Apoptosis and Necrosis

Cell death is imperative in the development of a healthy organism, as well as in the
maintenance of homeostasis that is necessary for life. One major type of cell death, apoptosis,
plays an essential role in this delicate equilibrium. The average adult sheds 10 billion cells each
day to preserve this balance (1). Apoptosis, or “programmed cell death”, allows an organism to
control the number of cells within a tissue, while guarding from the harmful effects of unwanted
cells. It is this form of programmed cell death that aids in regulating portions of the immune
system, contouring the shape of fingers from webbing during fetal development, as well as
eliminating cells that are superfluous, damaged, or infected (2, 3).
John Kerr and colleagues first defined apoptosis, in 1972, as a distinct process of cell
death, differing from necrosis (4).

This was followed by an important observation in the

nematode, Caenorhabditis elegans, that of 1,090 cells exactly 131 are lost through the process of
programmed cell death to form the adult worm (5). Pro-apoptotic proteins were later identified
as major players in this pathway leading to cell death in the nematode. Examples of such
proteins include the products of the nematode genes ced-3 and ced-4. Each of these gene
products share homology with genes in other species, suggesting that the mechanism of
apoptosis is highly conserved (6, 7).
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Cell death by apoptosis is most frequently characterized by morphological changes
within the cell. There are four basic phases of apoptosis that include initiation, execution,
disintegration, and elimination (6.).

Some noted features are shrinkage of the cell, DNA

fragmentation to approximately 200 base pairs, blebbing of the cell membrane, condensation of
chromatin, and the formation of apoptotic bodies (Figure 1) (8). Since the cells are ultimately
phagocytized, the lytic contents of the cells are not released into the surrounding environment;
consequently this form of cell death is devoid of inflammation (6).
Due to the important role of apoptosis as a regulator of cellular homeostasis, modification
of this process can have deleterious effects on an organism. Insufficient apoptosis correlates
with the accumulation of unwanted or damaged cells, which may ultimately result in malignancy
or autoimmune diseases (1, 9, 10). In contrast, excessive apoptosis has been associated with a
variety of maladies, for example, Alzheimer’s and Parkinson’s diseases (8).
In the past a clear line could be drawn between apoptosis and the other major type of cell
death, necrosis. These parameters allowed necrosis to be characterized by swelling of the cell,
rupturing of the plasma membrane, and release of cellular contents into the surrounding
environment leading to inflammation (Figure 1).

However, current research suggests that

although morphologically different, at times the two routes leading to cell death can overlap and
may even share common pathways (11). In various diseases including cancer, autoimmune
diseases, and neurodegeneration, apoptosis can occur in association with necrosis (12). This
overlap is illustrated in another type of cell death, “aponecrosis”, that is considered an
intermediate between apoptosis and necrosis (13).

2

Normal

Figure 1: Morphological Changes Observed in Cell Death
On the right, the figure depicts the changes seen during apoptosis. Upon apoptotic stimuli, the
cell begins to condense; this is followed by DNA fragmentation. The cell breaks off into smaller
membrane-bound “apoptotic bodies”, that will eventually be phagocytized. In contrast, the left
portion of the figure represents the morphological changes seen during necrosis. These include
cell swelling that leads to the lysis of the cell, and the release of intracellular components into the
surrounding tissue (picture taken from: http://www.bioweb.uncc.edu/Faculty/Hughes/).

3

1.2 Caspases-Mediators of Apoptosis

The role of caspases in programmed cell death was elucidated when homology was
observed between the cell death genes of the nematode, C. elegans, and mammals (14). Much of
the changes that can be observed within an apoptotic cell are the result of these homologous gene
products, known as caspases, which cleave substrates after an aspartate residue. Currently,
fourteen distinct members of this family of cysteine proteases have been identified (15).
Within this family of caspases, those involved in the apoptotic pathway are subdivided
into two groups, the initiator and the effector caspases. The initiator caspases, also termed
“upstream caspases”, include caspase-8, caspase-9, and caspase-10. Effector or “downstream”
caspases are comprised of caspases –3, -6, -7. In response to an apoptotic signal, initiator
caspases function to launch the apoptotic cascade by activating downstream effector caspases
which break down the cell (16).
The specificity of each caspase for a substrate is determined by a sequence of four amino
acids that is upstream to the cleavage site of the substrate. This cleavage may either activate the
substrate or render it inactive so that it may no longer properly function. Some substrates of
downstream caspases include cytoskeletal proteins, inhibitors of endonucleases, or proteins
involved in signaling or repair. Ultimately resulting in the biological and morphological changes
seen in cell death (17).
Caspases are made up of three domains: a small subunit, a large subunit, and an Nterminal pro-domain. Initially, caspases are expressed within the cell as zymogens, or procaspases, and remain inactive until each domain is separated by proteolytic cleavage.
4

A

heterodimeric association of the large and small subunits, which later join to form a tetramer,
follows this cleavage (16). Initiator caspases have a longer pro-domain that includes a site for
protein-protein interaction. For caspase-8 and caspase–10 this domain is labeled DED, or death
effector domain.

The remaining initiator caspases including caspase-9 contain a caspase

activation and recruitment domain (CARD). Both domains, through their interaction with other
signaling proteins, take part in controlling this complex cascade leading to programmed cell
death (7, 18).

1.3 Pathways of Cell Death

At present, two major mechanisms of apoptosis regulation have been defined. They are
the caspase dependent and the caspase-independent pathways (Figure 2). The caspase-dependent
pathway is composed of two independent sub-pathways (19).

One, the extrinsic pathway,

involves the initiation of death receptor molecules on the surface of the cell. Second, the
intrinsic pathway, is mediated primarily through the mitochondria by various apoptotic signals
(10). Although each pathway originates from a different location within the cell, the two
converge with the activation of downstream effector caspases that result in the morphological
changes seen in an apoptotic cell. The caspase independent pathway does not involve the
activation of caspases, but instead executes cell death through other proteins. For example,
apoptosis inducing factor (AIF), is released from the mitochondria, translocates to the nucleus
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and induces apoptosis. Proteins such as Endonuclease G, granzymes, and calpains have also
been shown to behave as proteases (7, 18, 20, 21).
The extrinsic pathway propagates the death signal following the binding of a ligand to a
member of the tumor necrosis factor (TNF) superfamily of death receptors, located on the
surface of the cell. Six various death receptors have been identified and include: CD95, TNFR1, DR3, TRAIL-R1, TRAIL-R2, and DR6 (22). Each of these transmembrane death receptors
contain a death domain located on the intracellular surface of the cell. This domain functions in
binding to signaling molecules involved in the apoptotic pathway. Once a ligand binds to its
respective receptor, the receptor trimerizes and then recruits various adaptor molecules that bind
to the death domain. This complex is referred to as the death inducing signaling complex
(DISC) (23). The adaptor molecules contain a death effector domain at their amino terminus that
intimately interacts with initiator procaspase-8 leading to its activation. This signal is then
transmitted to downstream caspases, resulting in apoptosis of the cell (6).
The intrinsic pathway is activated in response to various stimuli often referred to as
“cellular stress”. These stressors, which include among others: ionizing radiation, cytotoxic
drugs, and free radicals, are believed to cause a change in the mitochondrial membrane potential.
This alteration in the membrane integrity leads to the release of a variety of pro-apoptotic
proteins into the cytosol. One such protein, cytochrome c, forms a complex with the adaptor
protein, Apaf-1, and ATP (24). This complex referred to as the apoptosome, then recruits and
activates procaspase-9 (19, 20).

Once active, caspase-9 proteolytically activates effector

caspases, including procaspase-3, generating the morphological and physical changes in an
apoptotic cell (16, 20).
6

Both the intrinsic and extrinsic pathway interconnects with the pro-apoptotic protein Bid.
Bid is a member of the BH3 only, Bcl-2 family of proteins (6). This protein shares homology
with the BH3 domain of the founding molecule of this family, Bcl-2 (25). Bid is processed into
tBid by caspase-8 of the extrinsic pathway. Once truncated, tBid translocates to the mitochondria
where it may interact with other proapoptotic proteins, such as Bax and Bak (26). Though the
mechanism is not yet completely clear it is known that truncated Bid ultimately promotes the
release of cytochrome c from the mitochondria (22).

Figure 2: Pathways of Apoptosis
This figure is a schematic representation of the extrinsic, intrinsic, and caspase-independent cell
death pathways. The extrinsic pathway is activated through the stimulation of death receptors on
the surface of the cell. While, the intrinsic pathway is activated through various cellular
“stressors” (20). Both pathways converge at the mitochondria, where the release of a variety of
apoptotic proteins occurs. Among these is cytochrome c, which binds to Apaf-1, and caspase-9
forming the apoptosome. Additionally, Omi/HtrA2 and Smac//DIABLO are able to bind to
XIAP, an endogenous inhibitor of caspases, thereby alleviating the inhibition of caspases and
promoting apoptosis (7).
7

1.4 Preventing Apoptosis-Inhibitors of Caspases

The proteolytic cleavage of proteins by caspases is an irreversible event, therefore, it is
essential that not only the activation but also the activity of these proteases be tightly regulated
within the cell. Inhibitors of apoptosis (IAPs) are a class of proteins that function by binding to
and inhibiting caspases so that healthy cells may survive (20).
IAPs were originally identified in baculoviruses where they functioned to inhibit
apoptosis in host cells during viral infection. Since then the evolutionarily conserved IAPs have
been found in viruses, yeast, flies, and mammals (8). Two motifs have been recognized as part
of the structure of IAPs. All IAPs contain anywhere from one to three baculovirus IAP repeat
domains (BIR), which are made up of approximately 70 amino acid residues. The BIR domain
seems to be mandatory for the anti-apoptotic property of these proteins, and in some cases has
been found to directly interact with caspases. Additionally, a RING finger domain can be found
at the carboxy terminus of some inhibitors of apoptosis. Proteins that contain this RING domain
are able to ubiquitinate other proteins in addition to initiating their own degradation (18, 27).
Currently, there are eight IAPs that have been identified: XIAP, c-IAP1, c-IAP2, NAIP,
Survivin, Bruce, Livin, and ILP-2. These inhibitors of apoptosis are able to bind to either the
pro-caspase or active form of caspases to inhibit their activity thereby preventing caspasedependent programmed cell death (7).
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1.5 Inhibitors of IAPs: Smac and Omi

In order for a cell to undergo the process of programmed cell death, the inhibition of
caspases by IAPs must be terminated. Three proteins, Reaper, Hid, and Grim, originally
identified in the insect Drosophila melanogaster perform this function (28). Recently, two other
proteins, Smac/Diablo and Omi/HtrA2, were identified as mammalian homologs of these
proteins. Omi is the focus of this study.
Both Smac/DIABLO and Omi/HtrA2 are nuclear encoded mitochondrial proteins that
share an amino terminal sequence homology with the Reaper, Hid, and Grim proteins (29). This
homologous sequence is referred to as the IAP binding motif (IBM). This sequence allows these
proteins to bind to IAPs, permiting their release from caspases consequently enabling apoptosis
to take place (7).
Smac (Second Mitochondrial Activator of Caspases) or DIABLO (Direct IAP Binding
Protein with Low pI) is initially made as a 29 kDa precursor protein. This precursor translocates
to the mitochondria where its mitochondrial localization signal is removed, generating the
mature protein of 23 kDa. Upon apoptotic stimuli mature Smac/DIABLO is then released from
the intermembrane space of the mitochondria into the cytosol, where it is able to bind to and
sequester IAPs. Smac/DIABLO has been shown to bind to XIAP, c-IAP1 and c-IAP2, and
Survivin. This binding to XIAP is primarily meditated through the BIR2 and BIR3 domains
(30).

9

1.6 Characterization of Omi

Omi/HtrA2, was originally isolated as an interactor of Mxi2, the alternatively spliced
form of the p38 stress activated kinase. Omi is a serine protease containing a high homology to
the bacterial HtrA heat shock protease (31). The HtrA protein functions at higher temperatures
as a protease and at lower temperatures as a chaperone. The Htr, or high temperature
requirement, family of serine proteases is highly conserved from bacteria to humans (9). Omi is
ubiquitously expressed, while the alternatively spliced form, D-Omi, is expressed only in the
kidneys, thyroid, and colon (32). In healthy human cells Omi is restricted to the intermembrane
space of the mitchondria, however, upon apoptotic stimuli it is released into the cytosol.
Furthermore, the protease seems to be up-regulated during heat shock, ischemia or reperfusion,
and endoplasmic reticulum stress (31).
Omi shares some characteristics with Smac/DIABLO but still maintains separate
functions. Omi/HtrA2, like Smac/DIABLO, is known for its ability to inhibit IAPs, however, in
this case it is through irreversible cleavage. In a similar fashion to Smac/DIABLO, Omi/HtrA2
is translocated to the mitochondria, where the protein is processed from the 50 kDa precursor to
the 36 kDa mature protein. Omi/HtrA2 has been found to interact with and inhibit XIAP,
thereby initiating apoptosis in a caspase-dependent fashion. Upon apoptotic stimuli Omi/HtrA2
is released into the cytosol where it binds to XIAP, however unlike Smac/DIABLO, Omi/HtRA2
binds preferentially to the BIR3 domain of XIAP. This interaction prevents the inhibitor from
binding to caspase-9 thereby averting the activation of downstream effector caspases –3, -6, and
–7 (29) Additionally, this protein has been shown to interact with cIAP1 and cIAP2. In contrast
10

to Smac/DIABLO, Omi/HtrA2 does not bind to Survivin. Furthermore, Omi has also been found
to induce cell death through a caspase-independent mechanism, observed only when Omi is
overexpressed in cells (30, 31).
Omi/HtrA2 shares homology with two other known proteases, HtrA1/L56 and
HtrA3/PRSP (pregnancy related serine protease). HtrA1/L56 has been shown to be in higher
concentration in osteoarthritic tissue, and at lower levels in fibroblasts transformed with SV40
virus. Both HtrA1 and HtrA3 are significantly expressed in placental tissue (33). While HtrA1
and HtrA3 share high functional homology, Omi is limited to having homology with these
proteins only at the carboxy terminus of the protein. The amino terminal end of Omi contains a
regulatory domain that is not present in the other serine proteases. Interestingly, each of the
three proteases contains a highly conserved proteolytic domain. Although the function of HtrA1
and HtRA3 is not yet elucidated, the similarity between these two proteins suggests that they
may in fact have similar functions (34).
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Figure 3: Sequence Comparison of Human HtrA Proteins and Homolog in E. coli
The alignment shows the similarities and differences between the three known HtrA family
proteins as well as that of E. coli. Catalytic triad residues are boxed in red and the secondary
structures are indicated above the sequences (35).
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Figure 4: Domain Comparison of the Human HtrA Family
The diagram shows the differences between members of the HtrA family. HtrA1 and HtrA3
show a high degree of similarity, both having a signaling peptide (SP), IGF-binding domain (IB),
a Kazal domain (Kazal), a trypsin like domain (trypsin), in addition to a PDZ domain (PDZ). In
contrast, Omi contains an N-terminal regulatory domain instead of the SP, IB, and Kazal. For
each domain the percent homology to HtrA1/L56 is shown (34).
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1.7 Structure of Omi

Omi/HtrA2 contains three major domains including a regulatory domain at the amino
terminus, a centrally located catalytic domain, and a single PDZ domain at the carboxy terminus.
Within the regulatory domain exists a mitochondrial targeting sequence (MTS), a predicted
transmembrane region, a phosphorylation site, and a SH3 binding domain. In addition, upstream
to these features there is PRAXXTXXTP sequence that is repeated three times (31, 36). The
serine protease’s catalytic domain is comprised of three amino acids His 198, Asp 228, and Ser
306. This catalytic triad is folded with high similarity to that of trypsin, and is necessary for
Omi’s protease activity. Lastly, the PDZ domain is involved in interactions with other proteins,
through its ability to recognize hydrophobic residues (35).
Omi is synthesized as a 458 amino acid precursor.

Upon translocation to the

mitochondria, 133 amino acids at the N terminus of the precursor are removed by cleavage. This
exposes the conserved AVPS motif present in mature Omi that recognizes and binds IAPs (29).
The mature form of Omi is composed of 7 αhelices and  βstrands. Together these structures
form the serine protease domain as well as the PDZ domain (35).
When crystallized, the mature form of Omi/HtrA2 forms a homotrimer.

This

trimerization generates a pyramid structure housing the IBM sequences at the top and the PDZ
domain at the bottom. The serine protease domain in addition to the N terminal sequences
controls formation of this pyramid. Additionally, the formation of this structure seems to be
imperative in the proteolytic pro-apoptotic function of Omi. A working model, proposed by Li
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et al, suggests that perhaps the binding of a protein to the PDZ domain, leads to a conformational
change in the trimer, which allows access to the catalytic site of the protease (35).

Figure 5: Functional Domains of Omi
Omi contains an N-terminal regulatory domain, a catalytic domain, and a C-terminal PDZ
domain. The regulatory domain contains a mitochondrial targeting sequence (MTS) and three
PRAXXXTXXP motif of unknown function. The mature form of Omi lacks the first 133 amino
acids and has an exposed AVPS motif (31).

Figure 6: Trimeric Organization of Omi
Crystal structure analysis of Omi revealed that the active protease forms a trimer. Each subunits
catalytic domain mediates the arrangement of this structure. The PDZ domain is at the base of
the structure, while the IAP binding motif is situated at the top (35).
15

1.8 PDZ Domain of Omi

Recognized over 10 years ago, PDZ domains were originally identified in signaling
proteins, as regions of high sequence homology. These domains have recently been identified
as important protein-protein interacting regions necessary in a wide variety of proteins and
diverse organisms. The PDZ domain is named after the first three proteins that contained a
similar amino acid sequence: the post-synaptic density protein PSD-95, the Drosophila
melanogaster Discs Large protein, and Zonula occludens 1 protein Zo-1 (37, 38). Presently, as
many as 259 proteins within the human genome, have been suggested to contain PDZ domains
(39).
Approximately 90 amino acids in length, PDZ domains specialize in binding to specific
C-terminal motifs.

These motifs are within 6 amino acids in length and require a free

carboxylate group. Crystallographic data suggest that the binding of these C-terminal residues
interact directly with the peptide binding groove (40). Hydrophobic in character, most PDZ
domains select for a hydrophobic C-terminal residue (38, 41).
PDZ domains can be divided into three main groups for classification purposes. The
distinction between these classes can be determined by the interaction at P0 and P-2. In class I,
the PDZ recognizes a serine or threonine at the P–2 position, as is the case with PSD-95. For the
Class II PDZ domain, a hydrophobic residue occupies the P0 and P–2 positions. The third class
of PDZ favors a negatively charged amino acid at P-2. A fourth class of PDZ has been identified
that prefers a negatively charged amino acid at the P0 position (42).
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In contrast to this classification scheme, Omi does not fall into any of these categories of
PDZ domains. The binding selectivity of Omi/HtrA2 PDZ specificity has been shown to favor a
valine or isoleucine at P0. This amino acid is preceded by residues rich in either tyrosine,
phenylalanine, or large aliphatic groups at positions P-1, P-2, and P-3 (43).

Figure 7: The PDZ Domain of Omi
The PDZ domain of Omi mediates the activity of the protease. After binding to a substrate the
PDZ domain opens exposing the proteolytic domain (35).
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1.9 Multiple Functions of Omi

In order to understand the various functions of Omi it might be necessary to identify all
the physiological substrates of this protease as well as any other interacting proteins that could
regulate its function. To date, Omi has been identified as an active participant in both caspasedependent and caspase-independent cell death (44). Additionally, Omi has been suggested to
have a unique housekeeping role in mitochondria (45).
Most of the studies published on Omi deal with its role in the caspase-dependent pathway
of apoptosis. Omi is now known to activate caspase-dependent cell death by blocking and
removing inhibitors of apoptosis proteins (IAPs). This function of Omi is carried out via two
distinct mechanisms in the cytoplasm. One mechanism involves direct binding of Omi to IAPs
which disrupts their association with active caspases (46). In the second mechanism, Omi is able
to degrade and irreversibly remove IAPs. Omi does this by using its proteolytic activity after
binding to the inhibitors(29, 36, 44, 47, 48). Inactivation of IAPs, in turn, leads to caspase-9
activation and eventually to apoptosis. The interaction of Omi with IAPs is mediated through the
N-terminal AVPS of the mature Omi protein (28, 44). This AVPS motif is also found in all
known IAP interacting proteins including Drosophila homologs.
Furthermore, Omi is involved in the caspase-independent pathway of cell death and is
able to induce an “atypical form” of apoptosis (28, 44). This is independent of its AVPS motif,
and instead relies entirely on its ability to act as a protease. This form of cell death is observed
in Omi proteins lacking the exposed AVPS motif at their N-terminus but it is not seen in serineprotease inactive mutants (28, 44).
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Lastly, Omi has been identified as a mediator of homeostasis within the mitochondria
under normal physiological conditions. In Mnd2 mutant mice, a missense mutation resulting in a
Ser276Cys greatly reduces the protease activity of Omi/HtrA2 without affecting its protein levels
or sub-cellular localization. This suggests that the function of Omi in mitochondria may involve
the cleavage of specific substrates (45).

These mice display signs of muscle wasting,

neurodegeneration, and death by 40 days of age. The fact that these knockout mice show a
neurodegenerative phenotype, suggests that perhaps a primary function of Omi, at least in mice,
may lie within the mitochondria (45). This feature would concur with other pro-apoptotic
proteins, such as cytochrome c and endonuclease G, that also have unique mundane functions in
the mitochondria(49).
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CHAPTER TWO: MATERIALS AND METHODS

2.1 Construction of LexA- OmiCAT and LexA-HtrA1/L56 Baits

2.1a Polymerase Chain Reaction
The following primers were used in the PCR reaction for the cloning of the catalytic
domain of Omi (amino acids 134-340) and HtrA1/L56 into pGILDA.
Primer A 5’ OmiCAT (MfeI):
5’ CCC AAT TGG CCG TCC CTA GCC CGC CGC CC-3’
Primer B 3’ OmiCAT (XhoI):
5’ GGC CTC GAG TCA TCC GGA GGA GGA ATT CTT CTT-3’
Primer C 5’ HtrA1/L56 (MfeI):
5’ CGC AAT TGG GGC AGG AAG ATC CCA ACA GTT TGC GC-3’
Primer D 3’ HtrA1/L56(XhoI):
5’- GGC TCG AGC TAT GGG TCA ATT TCT TCG-3’
The restriction sites incorporated into each primer, MfeI or XhoI, are underlined. Each
PCR reaction was performed in 50µl volume using 20ng of template DNA, 10ρM of each
primer, 5µl of 10X PCR buffer + Mg (Roche Diagnostics Corp.), 1.5 units of Taq polymerase
(Roche Diagnostics Corp.), 100 µM dNTP (BD Biosciences). The reaction is placed in a thermal
cycler and after an initial denaturing at 95°C is passed through the following cycle 25 times:
95°C denatur for 30s, variable annealing temperature (based on primer) for 40s, 72°C elongation
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for a variable length of time based on size of PCR product. This followed by a final 7 minute
elongation step at 72°C. Each PCR reaction is performed twice, the products of the reactions are
then combined and precipitated.

2.1b Agarose Gel Electrophoresis
1.0 g of dried agarose (FMC BioProducts ) was added to 100ml 1X TAE (0.04M Trisacetate, 0.001M EDTA). This mixture was then microwaved until all agarose had completely
dissolved (≈ 2 minutes). The volume was then brought up to 100ml again with water and the
solution was allowed to cool. Ethidium Bromide was then added to a final concentration of
0.5µg/ml before pouring the solution into a gel tray. After the gel solidified, the combs were
removed. 1X TAE electrophoresis buffer was added to the electrophoresis apparatus until the
buffer just covered the gel.

2.1c Preparation of Samples for Agarose Gel Electrophoresis
1µl of 10X gel-loading buffer made of 30% glycerol (Fisher), and 2% Orange-G (Sigma)
in 1X TAE, was added to DNA. The final volume was brought up to a minimum of 10µl, and
the mixture was then loaded in a well. DNA markers (Bioline- 40ng/µl HyperLadder or 50ng/µl
Lambda DNA BstEII Digest) were used to estimate the size of the DNA sample. Electrophoresis
was performed at 50-120V, until the dye migrated the appropriate distance.
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2.1d DNA Precipitation
3M Sodium Acetate, pH 5.5 was added to a DNA solution at 1/10 the volume of the
sample. Addditionally, 2X the sample volume of 100% ethanol –20°C was also added. The
sample was mixed well and stored at –20°C for a minimum of 20 minutes. The sample was then
centrifuged for 20 minutes at 4°C and 14000 rpm. The supernatant was then discarded. The
pellet was washed in 300µl of 70% ethanol –20°C, and centrifuged again for 5 minutes. The
supernatant was then discarded and the pellet was dried for 10 minutes in the speed vacuum.
The pellet was then resuspended in the appropriate volume of dH2O or Tris EDTA, pH 8.0.

2.1e Restriction Enzyme Digestion
Double stranded DNA was incubated with the appropriate amount of restriction enzyme
and its respective buffer as suggested by the supplier. Reactions were then incubated at 37°C for
1-4 hrs depending on the enzyme efficiency. For two separate digestions, DNA was precipitated
after the first digestion and resuspended in the appropriate buffer needed for the second
digestion. A general protocol for a 50µl reaction is as follows:

5µl

Restriction Enzyme 10X buffer

0.5µl BSA, 10µg/µl
1 µl DNA, 1µg/µl
42µl sterile, dH2O
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1.5µl Restriction Enzyme,10U/µl

2.1f Ligation
DNA concentration of 1µl of insert and 1µl of vector were estimated using gel
electrophoresis (2.1b). The ligation was performed using insert and plasmid DNA from gel
purified RE digestion, an the Fast-Link DNA ligation Kit (EPICENTRE TECHNOLOGIES). In
general a bmolar concentration of 2:1, insert:vector was used. A general protocol for a 15µl
reaction is as follows:

1.5µl Fast-Link Ligation Buffer
1.5µl 10mM ATP
1 µl

Fast-Link DNA Ligase

x µl insert
x µl

vector

xµl

dH2O

The mixture is then incubated at room temperature for 5 minutes. This is followed by
ligase deactivation at 70°C, for 15 minutes.
To precipitate the reaction, the ligation reaction is brought to a final volume of 50µl using
dH2O. 500µl of room temperature N-butanol is added and the solution is mixed very well. The
sample was then centrifuged for 10 minutes at 4°C and 14000 rpm. The supernatant was then
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discarded. The pellet was washed in 300µl of 70% ethanol –20°C, and centrifuged again for 5
minutes. The supernatant was then discarded and the pellet was dried for 10 minutes in the
speed vacuum. The pellet was then resuspended in the appropriate volume, ≈4µl, of dH2O.

2.1g Bacterial Transformation
The DNA to be transformed was added to 100µl of a competent bacterial cell suspension
(either DH5α, BL21, or KC-8), mixed gently, and transferred to an electroporation cuvette (0.2
cm electrode gap, BIO-RAD) that had been cooled to 4°C. The cuvette was placed in the Gene
Pulser (BioRad) that delivers a single exponential decay pulse of 2.5V. 1ml of room temperature
LB without antibiotics was then added immediately. The entire mixture was then transferred to a
sterile 15ml centrifuge tube and incubated at 37°C with shaking for 45 minutes. 50µl -150µl of
the solution was then plated on agar plates containing the appropriate antibiotic, and incubated
overnight at 37°C.

2.1h Isolation of Plasmid DNA from Bacteria: DNA Qiaprep Spin Miniprep
Plasmid DNA was isolated using QIAprep Spin Miniprep Kit according to the
manufacturers instuctions (QIAgen). A single bacterial colony is chosen and grown overnight
with shaking in 4ml LB broth with the appropriate antibiotic. 1.5ml of the bacterial culture is
transferred to a microcentrifuge tube and centrifuged at 14000 rpm for 2 minutes.

The

supernatant is then aspirated. The pelleted bacteria is resuspended in 250µl of Resuspension
Buffer P1, stored at 4°C, containing RNase (100mg/ml). 250µl of Lysis Buffer P2 is then added,
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and the tube is gently inverted 4-6 times. The lysate is neutralized and adjusted to high-salt
binding conditions by adding 350µl of neutralization Buffer N3. The tube is the immediately and
gently inverted 4-6 times and then centrifuged at 14000 rpm for 10 minutes at room temperature.
The supernatant is then transferred to a QIAprep spin column is resting in a 2ml collection tube.
The column is centrifuged again for 1 minute and the flow-through is discarded. The QIAprep
spin column is then washed using 500µl binding buffer (PB) and centrifugation at 14000 rpm,
for 1 minute at room temperature. The flow-through is discarded. An additional wash is
performed using 750µl of wash buffer (PE) and centrifugation at 14000 rpm, for 1 minute at
room temperature. The flow-through is discarded. The residual wash buffer is then removed
with an additional centrifugation for 1 minute. The QIAprep spin column is then placed in a
clean 1.5ml microcentrifuge tube. By adding 50µl of Elution Buffer, EB, (10mM Tris-HCL,
pH8.5) to the center of the column, letting stand for 1 minute, and centifuging at 14000 rpm, for
1 minute at room temperature, the DNA is eluted.

2.1i Isolation of Plasmid DNA from Bacteria: DNA-Boiling Method Miniprep
A single bacterial colony is grown overnight with shaking in 4ml LB broth with the
appropriate antibiotic. The culture is then placed on ice. 1.5ml of LB containing bacteria is
transferred to a microcentrifuge tube and centrifuged at 14000 rpm for 2 minutes.

The

supernatant is then aspirated. The pellet is resuspended in 300µl of filtered STET (8% Sucrose,
5% 100X Triton, 50mM Tris-HCl pH8, and 50 mM EDTA). 25µl of 10mg/ml lyzozyme is then
added to each sample. The sample is vortexed briefly and placed in boiling water for 45
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seconds. Then the sample is centrifuged at 4°C and 14000 rpm for 15 minutes. 200µl of the
supernatant is transferred to a new 1.5ml microcentrifuge. To this, 230µl of -20°C isopropanol is
added and the samples are mixed well. The tubes are placed at –20˚C for 10 min and the
centrifuged again at 4°C and 14000 rpm for 5 minutes. The supernatant is discarded and the
pellet is washed with 300 µl of 70 % ethanol (-20°C). The pellet is then dried for 10 minutes in
the speed vacuum. The pellet is then resuspended in dH2O or TE.

2.1j DNA Sequence Analysis
CEQ 2000 Dye Terminator Cycle Sequencing was performed using the Quick Start Kit
(Beckman). The reactions were performed in 0.2 ml thin walled tubes. All reagents were kept
on ice while the sequencing reactions were prepared. Each reaction was performed in 10 µl
volume using the appropriate amount of template DNA (based on the size of the insert), 3ρM,
and dH2O (to adjust the volume to 10 µl). The components were mixed and then denatured for 2
minutes at 95°C. Next, 3µl of DTCS Quick Start Master Mix was added. The reaction is placed
in a thermal cycler and is passed through the following cycle 30 times: 96°C denature for 20s,
50°C for 20s, 60°C for 4 minutes. This is followed by holding at 4°C. To this reaction 2.5µl of
Stop Solution (1.5M NaOAc, 50mM EDTA prepared fresh by mixing equal volumes of 3M
NaOAc and 100mM EDTA) and 1µl of 20mg/ml glycogen (Beckman Coulter) is added. The
reaction is then transferred to a 1.5µl microcentrifuge tube and mixed thoroughly. To this 60µl
of -20°C 100% ethanol is added. This is centrifuged immediately at 4°C and 14000 rpm for at
least 15 minutes. This supernatant is carefully removed with a pipette and discarded. The pellet
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is washed with 200µl of 70% ethanol (-20°C). The supernatant is again carefully removed with a
pipette and discarded. The pellet is dried in the speed vacuum for 15 minutes and resuspended in
20 µl of Sample Loading Solution (Beckman Coulter).

2.2 Yeast Two Hybrid Interactions

2.2a Yeast Transformation
50ml of appropriate medium is inoculated with a single yeast colony to be transformed,
and grown overnight with shaking at 30°C. The following day in a sterile 50ml Falcon tube the
cells are harvested by centrifugation at 3800 rpm for 5 minutes. The supernatant is then
discarded. The pellet is washed by resuspension in 10mL TE pH 7.5, and then centrifugation at
3800 rpm for 5 minutes. The supernatant is discarded. The pellet is resuspended in 5 ml LA
(0.1M LiOAc in TE) and transferred to a 15 ml Falcon tube. The solution is then incubated for
two hours at 30°C with shaking. The cells are harvested by centrifugation at 3800 rpm for 5
minutes. The supernatant is discarded and the pellet is resuspended in a variable amount, usually
≈5ml, of LA (depending on the size of the pellet). The yeast is then separated into 300µl
aliquots in 1.5ml microcentrifuge tubes. Next, 1µg of DNA to be transformed is added along
with 100µg of denatured salmon sperm DNA. To this, 700µl of 50% PEG4000 (diluted in
100ml of dH20) and the solution is mixed until homogeneous. Then the yeast is incubated in a
30°C water bath for 30 minutes. The yeast are then moved to a 42°C water bath for 15 minutes.
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The cells are then centrifuged for 3 minutes at 14000 rpm and the supernatant is aspirated. The
pellet is resuspended in 300µl of TE pH 7.5. 50µl-150µl of the solution is then plated on agar
plates containing the appropriate selective medium, and incubated for 2 days at 30°C.

2.2b Yeast Drop-Out Medium
The yeast strain used in all experiments was auxotropic, which allowed for selection by
using specially prepared drop out medium. A liter of drop out medium contains the following: 2g
appropriate “drop out” powder (lacking the appropriate amino acids) (50), 6.7g Yeast Nitrogen
Base without amino acids (Sigma) and 900 ml of sterile water (for agar plates 20g of agar (USB)
was added as well).

The bottle was autoclaved and 2% weight-by-volume carbon source

(Glucose or Galactose) was added.

2.2c Yeast Western Blot
3ml of yeast medium was inoculated with the yeast to be tested, the positive control, or
the negative control, and incubated overnight at 37°C with shaking until an optical density of
0.4-0.7 at 600nm. The yeast was transferred to a 1.5ml microcentrifuge tube and centrifuged at
14000 rpm for 3 minutes. The supernatant was then aspirated and the pellet was resuspended in
50µl of 1X SDS-sample loading buffer (10% β-mercaptoethanol, 6% SDS, 20% glycerol and
1/40 X stacking buffer and 0.2mg/ml bromophenol blue). The samples were vortexed, placed on
ice and then boiled for 5 min, along with a pre-stained protein marker (BioLabs). A short spin
was performed to remove large cell debris. 20µl of sample and 15µl of marker were loaded on a
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pre-cast gradient 4-20% Tris-Glycine gel (Invitrogen). The proteins were transferred to a PVDF
membrane by semi-dry electrophoresis using a BioRad transfer blot. For proper transfer PVDF
membrane (PALL) was first activated in 50 ml methanol (CH3OH). Gel, membrane and 2 filter
papers were equilibrated in 250 ml transfer buffer (9.6mM Tris, 7.8mM glycine and 20 %
CH3OH to a final pH ~9) for 5 min. The semi-dry transfer was arranged having the soaked filter
paper on the bottom, followed by the membrane, gel and a second sheet of filter paper on top.
The transfer machine was run for 1 hour at 15V. In order to block unspecific binding, the PVDF
membrane was incubated overnight at 4° C in 10 ml 2% nonfat milk powder in TBST (250mM
Tris pH 8, 1.25M NaCl and 0.1% Tween 20). The following day, either primary antibody αLexA-HRP (used for “bait” proteins)(Santa Cruz) or α-HA (used for “prey” proteins)(Sigma)
was diluted 1:1000 or 1:1500, respectively, in 5 ml 2% milk and used to incubate the membrane
for 4 hours at room temperature. Before incubating with the secondary AB the membrane was
washed in TBST for 5 minutes, and this was repeated 5 times. Secondary antibody Goat-αrabbit-HRP (Cappel) was used when analyzing prey proteins at a 1:15000 dilution. When
analyzing bait proteins, no secondary AB was used because the primary AB already contained
the HRP tag. Secondary AB, when appropriate, was diluted in 2% milk and incubated with
membrane for 1 hour. The membrane was washed in TBST for 5 minutes, and this was repeated
5 times. This was followed by two 5 minute washes in TBS (250mM Tris pH 8, 1.25M NaCl).
Proteins were detected by a chemiluminescence ECL kit (PIERCE).
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2.3 Screening Melanocyte Library

2.3a Yeast Two Hybrid: Interaction of Melanocyte Library
The yeast strain EGY48 was used as the host yeast strain for all two-hybrid interaction
experiments. This yeast strain has an integrated LEU reporter gene with an upstream LexA
operator, a pSH18-34 plasmid with an upstream LexA operator, and a LacZ reporter that directs
the synthesis of β-galactosidase (50). Special shuttle vectors are used to clone the bait and prey.
The melanocyte library was previously cloned in pJG4-5 (Zervos lab), which contains a
galactose inducible promoter. While the bait proteins Omi (Zervos lab), OmiPDZ (Zervos lab),
OmiCAT, and L56156-480 were cloned into pGILDA, which also contains a galactose inducible
promoter. The pGILDA vector is used for any bait, in this case Omi, whose continuous presence
is toxic to the yeast (50). Positive interactions between bait and prey were detected by the
presence of blue colonies when grown on GAL-Ura-Trp-His- selective medium plates containing
X-Gal.
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Figure 8: Yeast Plasmids: Map of pSH18-34, pJG4-5, and pGILDA Vectors
All vectors have a 2µ origin of replication in addition to Ampicillin resistance (AmpR). A
selectable marker is present to select for each plasmid when grown in yeast: URA3, TRP1, and
HIS3 in pSH18-34, pJG4-5, and pGILDA, respectively. (Picture taken from:
http://www.fccc.edu/research/labs/golemis/InteractionTrapInWork.html)

2.3b High Efficiency Yeast Transformation
A single yeast colony, EGY48 pSH18-34 pGilda-Omi134-458, was picked and grown
overnight at 30°C, with shaking, in 50 ml of U- H- Glu drop out medium. The next day the
culture was diluted to 300ml with the same medium and grown to an OD600nm of 0.9. Cells were
harvested by centrifugation at 3800 rpm for 5 min. Supernatant was discarded and the cells were
resuspended in 20ml of sterile H2O. Spin was repeated for 5 min 3800 rpm, and supernatant
discarded. Cells were resuspended in 20ml LA (0.1 M LiAc in TE) and spun again for 5
minutes. Lastly, the cells were resuspended in 5ml of LA. 100µl of competent yeast was
aliquoted into sterile eppendorf tubes and the following was added: 10µg DNA melanocyte
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library, 100µg of denatured salmon sperm DNA (carrier DNA), and 600µl of freshly prepared
40% PEG solution (50% PEG 4000 prepared in water then freshly diluted to 40% in LA
solution). The mixture was resuspended, making sure the solution was homogeneous. The
transformation reaction was incubated in a 30ºC water bath for 30 min, and then heat-shocked at
42ºC in water bath for 15 min.

Transformed yeast were centrifuged for 30 seconds, the

supernatant removed, and pellet resuspended in 500µl of sterile H2O. 300µl of resuspended yeast
was plated on 24 x 24 cm (Nalge Nunc) U-H-W- Glu selective plates using glass beads (Fisher)
and incubate at 30°C for two days.

2.3c Aliquoting Library
The number of colonies in a 2 x 2cm square was counted on 3 sample plates. An average
for the squares is obtained and multiplied with 126.6 (the number of 2x2 cm squares in one large
plate). This value is the average number of colonies per large plate. The plates are then placed
at 4°C so that the agar will harden. Using autoclaved glass slides and aseptic technique, the
colonies were scraped from the 10 plates and placed in a Falcon tube. Each plate was washed
two times with 10ml of sterile autoclaved water. The yeast were resuspended and distributed
evenly into 50ml Falcon tubes. Next, the yeast were centrifuged at 3800 rpm for 5 minutes. The
supernatant was discarded and the pellet was washed with 50ml sterile H2O, and centrifuged
again for 5 minutes. This wash was repeated again. Lastly, the pellet was resuspended, in a
volume equal to the size of the pellet, in filtered yeast freezing medium (65%glycerol, 0.1M
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MgSO4, 25 mM Tris, pH 7.4). The mixture was then aliquoted into small centrifuge tubes at
300µl each and placed in -80°C.

2.3d Titration
100µl of thawed “frozen melanocyte library” was grown in 5ml U-H-W- Gal/Raf for 5
hours at 30°C with shaking. Serial dilutions of this yeast culture are then prepared as follows:
Tube 1=100 µl from yeast solution in 900µl of sterile H2O -->1:500
Tube 2=100 µl from Tube 1 in 900µl of sterile H2O

-->1:5,000

Tube 3=100 µl from Tube 2 in 900µl of sterile H2O

-->1:50,000

Tube 4=100 µl from Tube 3 in 900µl of sterile H2O

-->1:500,000

Tube 5=100 µl from Tube 4 in 900µl of sterile H2O

-->1:5,000,000

100µl from each tube was then plated on U-H-W- Gal/Raf plates, and grown for two days
at 30°C. Then the colonies from plates 3-5 were counted and multiplied by the dilution factor.
This is done to determine the amount needed to be plated on a large U-H-W-L- Gal/Raf plate in
order to yield the correct number of colonies that will represent the entire library.

This

extrapolated amount is plated on 24 x 24cm (Nalge Nunc) U-H-W-L- Gal/Raf plates for growth
selection.
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2.3e Screening
After growth selection was performed on U-H-W-L- Gal/Raf, the positive colonies were
then streaked onto U-H-W- Glu plates, and grown for two days at 37°C. Next, the colonies were
streaked onto U-H-W- Glu/X-Gal and U-H-W- Gal/Raf/X-Gal plates. For color selection, positive
interactions between bait and prey were detected by the presence of blue colonies on the U-H-WGal/Raf/X-Gal plates and these were inoculated in U-H-W- Glu medium to select for the pJG4-5
melanocyte library plasmid. These were grown overnight at 30°C with shaking to release the
plasmid from yeast.

2.3f Release plasmid from Yeast
A single yeast colony was picked with a sterile toothpick and grown in 1ml U-H-W-Glu
medium overnight. Then, the culture was transferred to a screw cap microcentrifuge tube. The
yeast was centrifuged for 1 minute at 14,000 rpm. The pellet was resuspended in 200µl of yeast
lysis solution (2% TritonX-100, 1% SDS, 100mM NaCl, 10mM Tris pH 8.0, 1mM EDTA).
Approximately 0.3 g of glass beads (Sigma) was added to assist in the lysis along with 200µl of
Phenol-chloroform-isoamyl alcohol (25:24:1). The tube was capped and vortexed vigorously for
2 minutes or until the mixture became homogenous. The tube was centrifuged for 2 minutes to
separate the phases, and the upper aqueous phase was transferred to a new microcentrifuge tube.
DNA was precipitated as described in section 2.1d.
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2.3g Transformation of Plasmid into KC8
The plasmids extracted from the yeast were transformed into KC8 bacterial cells using
the transformation protocol in section 2.1g.

2.3h Sequencing of Melanocye Library Positive Interactors
Positive clones were extracted from KC8 bacterial cells using the miniprep protocol in
section 2.1h. These plasmids were then sequenced to identify the clone using the protocol in
section 2.1j.

2.3i Retransformation in Yeast
The positive interactors for Omi134-458 were retransformed into yeast containing pGILDAOmi134-458, pGILDA-OmiPDZ, pGILDA-OmiCAT, pGILDA-L56 using the yeast transformation
protocol in section 2.2a.

2.4 Construction of pJG4-5-HOPS and GFP-HOPS

2.4a Polymerase Chain Reaction
The following primers were used in the PCR reaction for the cloning of pJG4-5-HOPS
and pGFP-HOPS.
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Primer E 5’ pJG4-5-HOPS (EcoRI)
5’- CGG AAT TCA TGT TAA CTC TTA ATC TAG TTA AAC – 3’
Primer F 5’ pJG4-5-HOPS (EcoRI)
5’ – CGG AAT TCT ATG TTA ACT CTT AAT CTA GTT AAA C – 3’
Primer G 3’ pGFP-HOPS and pJG4-5-HOPS (SalI)
5’ – GCC GAC GTC GAC CTA TAT CAT AGT GAC TTC ATA TG-3’
The restriction sites incorporated into each primer XhoI and SalI are underlined. The
PCR products were then digested with the appropriate enzyme and cloned into either pEGFP-C1
(Clontech), pJG4-5, or pET28A (Novagen).
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Figure 9: Maps of pEGFP-C1 and pET-28a Vectors
(A) Map of pEGFP-C1 vector used in localization experiments (figure taken from:
www.clontech.com). (B) Map of pET-28a vector used in protein expression experiment (figure
taken from: http://www.emdbiosciences.com/html/NVG/AllTables.html).

37

2.5 Cleavage Assay

2.5a TNT
The following primer was used in the PCR reaction for the TNT reaction of pJG4-5HOPS:
Primer K 5’ pJG4-5 with T7 promoter and Kozak sequence
5’-TAA TAC GAC TCA CTA TAG GGG ACG ACC ATG GTG CCA GAT TAT GCC
TCT CCC-3’
Primer L 3’ pJG4-5
The PCR reaction was performed following the protocol in section 2.1a.
The general protocol for a 50µl TNT reaction is as follows:
TNT T7 Quick Master Mix (Promega)

40µl

[35S] methionine/cysteine (1,000Ci/mmol at 10mCi/ml) (Promega)

2µl

PCR generated DNA template

2.5-5µl

H2O

3-5.5 µl

The reaction is incubated at 30˚C for 1.5 hours

2.5b Degradation Assay
The product of the TNT reaction was incubated with mature his-tag purified Omi134-458 as
shown in Table 1. The reaction was performed in a final volume of 20µl.
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Table 1: Description of Cleavage Assay
+ve

-ve

[S35]-HOPS
5µl

[S35]-HOPS
5µl

Omi 134-458
5µl

Omi134-458
0µl

Omi Assay Buffer
10µl

Omi Assay Buffer
15µl

The mixture was incubated at 37˚C for 1 hour. 10µl of 2X sample loading buffer was
then added to the reaction and the proteins were resolved on a 12% SDS gel under denaturing
conditions.

2.6 Transfection in Hela Cells

2.6a Growing HeLa Cells
HeLa cells, human cervical carcinoma cell line, were grown using F12-Nutrient Mixture
(HAM) media (Life Technologies) supplemented with 10% FCS (Sigma), 2mM L-glutamine,
100U/ml penicillin and 100µg/ml streptomycin (Life technologies).
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2.6b Transfections and Immunofluorescence Microscopy
For immunofluorescence, the cells were grown on cover-slips. Approximately 70%
confluent cells were transfected with 2µg of pEGFP-HOPS using Lipofectamine Plus reagent
according to the instructions provided by the manufacturer (Life Technologies). After 24 hours,
the transfected cells were washed 3 times with PBS and fixed with 4% paraformaldehyde. The
cover-slips were then placed on glass slides using Fluoromount-G solution (Southern
Biochemical Association). The subcellular localization of GFP fusion proteins was monitored
using a LSM510 confocal laser-scanning microscope (Carl Zeiss).

2.7 Transfection in 293T Cells

2.7a Growing 293T Cells
293T cells, human fibroblast cells, were grown using DMEM media (Life Technologies)
supplemented with 10% FCS (Sigma), 2mM L-glutamine, 100U/ml penicillin and 100µg/ml
streptomycin (Life technologies), 1.5g/L sodium bicarbonate (Fisher), 1mM sodium pyruvate
(Sigma).
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2.7b Induction of Apoptosis
HEK-293T cells were transfected with either GFP-HOPS or DsRED-Omi134-458 using
Lipofectamin Plus reagent according to the manufacturers directions (Life Technologies). The
following morning the medium was removed.

Fresh 293T medium was treated with either

2mmol H2O2 or 2mmol Cisplatin. The new medium was added to the cells and 12 hours after
treatment the cells were analyzed.

2.7c Western Blot of Mammalian Cells
Twelve hours after treatment the cells were recovered by pipetting, and placed in a 2ml
microcentrifuge tube. The wells were washed with 500µl of PBS. The tubes are spun at 35004000 rpm for 3 minutes. The supernatant is aspirated. The pellet is resuspended in 150µl of
lysis buffer (1%Triton-X-100, 10%glycerol, 150mM NaCl, 20mM Tris pH7.5, 2mM EDTA,
protease inhibitor cocktail SIGMA). The mixture is then placed in ice for 10 minutes. The cells
are then lysed using a combination of freezing with dry ice for 2 minutes and then thawing the
cells at 37˚C for 1 minute. This process is repeated five times with a 30 second vortexing
between each repeat. The cells are spun at 4˚C and 14000rpm for 10 minutes. The supernatant
is then transferred to a new tube and the protein concentration is measured for equal loading
using a Bradford assay.
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2.8 Purification of HOPS133-233

2.8a Transformation of BL21
BL21 expression bacteria are used to for protein purification.

The bacteria are

transformed using 1µl of DNA from a 1:10 dilution of clean miniprep DNA, following the
protocol in section 2.1g.

2.8b Protein Purification
BL21 bacteria transformed with pET28a-HOPS133-233 were grown O/N in the appropriate
LB containing Kanamycin. The following morning the bacteria were placed in the appropriate
volume of medium with 50µg/ml. The culture was grown at 250rpm and 37˚C to an OD600 of
0.8. 1ml of bacteria was obtained before induction for analysis. The temperature was then
dropped to 25˚C and induction was performed using 1mM IPTG. Induction was done O/N. The
following morning 1ml of bacteria is obtained for analysis, and the remaining culture is spun at
6000rpm and 4˚C for 10 minutes. The supernatant is discarded and the pellet is placed on ice.
The pellet was resuspended in 25-40ml of Lysis Buffer which is composed of Binding Buffer +
4X Protease Inhibitor Cocktail (SIGMA) diluted to a concentration of 1:100. This mixture was
placed in a 50ml Falcon tube and lyzozyme (10mg/ml) is added 1:100; the mixture was placed at
30˚C for 15 minutes.

1% Triton X-100 was added and the solution was spun at room

temperature for one hour. The cells are then sonicated 3 times, each time for one minute and
then they were placed on ice for 1 minute. The mixture was then centrifuged at 4˚C 13000rpm
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for 30 minutes. The supernatant was filtered with .45micron filter and 4ml of 50% Ni-NTA
beads were added. This was mixed O/N at 4˚C. The next morning everything was placed in a
column and the flow through was collected for analysis. The column was washed 2 times with
50ml of 1X Binding Buffer (8X=400mM NaH2PO4, 2.4M NaCl, 80mM Imidazole, 0.4% NaN3).
Then the column was washed 2 times with 50ml of 1X Wash Buffer (8X=400mM NaH2PO4,
2.4M NaCl, 160mM Imidazole, 0.4% NaN3). The column is then eluted 2 times with 2ml of
Elution Buffer (4X=200mM NaH2PO4, 1.2M NaCl, 1M Imidazole, 0.2% NaN3). The eluant was
then dialysed in Dialysis Buffer (40mM Hepes and 200mM NaCl). The purified protein was
then subjected to SDS-PAGE to analyze purity.

2.9 Regulation Assay

2.9a Regulation Assay
Purified HIS-HOPS133-233 was incubated with either his-tag purified mature Omi134-458 or
his-tag purified inactive OmiS-C276 protein to see if HOPS133-233 has a regulatory role on the
protease activity of Omi. HOPS133-233 was incubated together with either Omi134-458 or OmiS-C276
for 10 minutes. 2µl of 2.5mg/ml β-casein was then added to the mixture. The final reaction
volume of 20µl was reached using Omi Assay Buffer (20mM NaH2PO4/Na2HPO4, pH 7.4,
200mM NaCl, 5% Glycerol). The samples were loaded side by side on a 12% SDS-PAGE and
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the gel was stained with Coomassie for 3 hours and destained with Destaining Solution
(20%Methanol, 10% Acetic Acid) overnight.

CHAPTER THREE: RESULTS

3.1 Cloning and Yeast Expression of LexA-Omi134-340 and LexA-L56157-485

DNA corresponding to the mature form of Omi134-458 protein, the catalytic domain (amino
acids 134-340) or the PDZ domain (amino acids 340-458) was cloned into the pGILDA yeast
expression vector. Using these three different baits, one could assess which domain of Omi a
potential interactor was binding.
In addition, as a control, DNA for the HtrA1/L56157-480 protein was also cloned into the
pGILDA vector. Since Omi and L56 share high sequence homology, this protein will be used to
determine the specificity of any interactors.
The catalytic domains of Omi and L56157-480 were expressed as Lex-A (DNA binding
domain) fusion proteins using the pGILDA vector as described in Materials and Methods.
Transcription of these bait proteins is under the control of a GAL1 promoter, and therefore are
only expressed in yeast in the presence of galactose. These constructs were transformed into
yeast cells and expression of the recombinant LexA-fusion proteins was monitored by Western
Blot analysis of yeast whole cell extracts grown either in glucose or galactose.
LexA- Omi134-340 has an estimated molecular weight of ≈43 kDa, which corresponds to
the estimated molecular weight of the catalytic domain, 23kDa fused with the LexA DNA-
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binding domain, ≈20kDa (Figure 10). LexA- L56157-480 has an estimated molecular weight of 56
kDa, which corresponds to the estimated molecular weight of L56157-480, ≈36kDa, fused with
LexA ≈20kDa (Figure 11).
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LexA-OmiCAT134-340
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Figure 10: Cloning and Yeast Expression of pGILDAOmi134-340
Yeast-expression of various baits in the presence of glucose or galactose. Lane 1: LexA-Omi134458 glucose; Lane 2: LexA-Omi134-458 galactose; Lane 3: LexA-Omi134-340 glucose; Lane 4: LexAOmi134-340 galactose.
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Figure 11: Cloning and Yeast Expression of pGilda-L56157-480
Expression of LexA-L56157-480 in the presence of glucose or galactose.
Lane 1: LexA-L56157-480 glucose; Lane 2: LexA-L56157-480 galactose; Lane 3: LexA-Omi134-458
galactose. The size of both recombinant proteins is very similar.
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3.2 Screening the Melanocyte cDNA Library

RNA was obtained from cultured, actively growing, human melanocyte cells. This RNA
was used to make cDNAs, which was then cloned unidirectionally as an EcoR1/Xho1 fragment
into the corresponding sites of the pJG4-5 vector (Zervos Lab). This melanocyte cDNA library
was used in the yeast two hybrid screening.
The mature form of Omi134-458 fused to LexA was used as the bait in this screening.
Additionally, two reporter genes, the LexAop-LEU2 gene allowing the growth of the colonies in
the absence of leucine and the LexAop-lacZ gene that directs the synthesis of β-galactosidase,
were included. The number of clones per plate was estimated by counting the number of
colonies in a 2x2 cm squares. Two squares were counted on each of the ten plates, averaged, and
then extrapolated to estimate the number of clones per plate. A total of 7X105 colonies were
present.
7 million primary yeast colonies were screened for cDNAs encoding proteins that
potentially interact with the mature form of Omi. Of these seven million colonies 100 colonies
were initially identified by their ability to grow on U-H-W-L- Galactose selective plates. These
were then tested on U-H-W- Glucose/X-Gal and U-H-W- Galactose/X-Gal plates. Fifty-one of
them were found to have a galactose dependent phenotype. Twenty-five of the colonies were
identified as false positives, correlating to either a blue colony on U-H-W- Glucose/X-Gal that
could not be further examined, or a white colony on U-H-W- Galactose/X-Gal that suggests no
protein-protein interaction (Figure 12).
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U-H-W- Glucose/X-Gal

U-H-W- Galactose/X-Gal

Figure 12: Melanocyte cDNA Library Screening
A positive interaction between the bait protein and the prey protein, leads to blue colonies on UH-W- Galactose/X-Gal. White colonies suggest a negative protein-protein interaction. Blue
colonies on the U-H-W- Glucose/X-Gal plate correspond to false positives.
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3.3 Characterization of Omi Interactors

The cDNA library plasmids, were rescued from each of the positive yeast clones, and
introduced into KC8 bacteria by electroporation. The prey plasmids were then isolated using a
Miniprep Kit (QIAGEN). The cDNAs were sequenced, and homology searches were performed
using the BLAST program provided by on the NCBI server (www.ncbi.nlm.nih.gov/BLAST/).
Screening in yeast was repeated using these 51 purified cDNA library plasmid as “prey” and
either LexA-Omi134-458, LexA-OmiCAT134-340, LexA-OmiPDZ340-458, or LexA-L56157-480 as the
“bait”.
The results of the yeast transformation revealed that of the 51 positive clones, 32 were
true positives. A positive interaction, resulting in a blue colony on U-H-W- Galactose/ X-Gal,
between one of the bait proteins (LexA- Omi134-458, LexA- OmiCAT134-340, LexA- OmiPDZ340-458,
and LexA- L56157-480) and the prey (interactors identified in melanocyte library cDNA screening)
corresponds to a + on the chart. However, a negative interaction yielding no color change,
corresponds to a – on the table. These 32 interactors were sequenced and 17 distinct family
proteins were identified. Each isolated cDNA is a true interactor of Omi, however, these
interactors may be localized in a different location then Omi under normal physiological
conditions.

This localization must be taken into consideration when choosing a particular

intereactor to characterize. There must be a possiblility that Omi is able to encounter the
interactor under normal conditions. One of these interactors we call HOPS, for HtrA/Omi
protein substrate, was selected for further characterization.

49

Table 2: List of Omi Interactors Isolated From a Human Melanocyte cDNA Library
NAME
Thyroid receptor
interacting protein 15
Complement component
1, q subcomponent/ p32
Macrophage migration
inhibitory factor
D-dopachrome
tautomerase
Nucleostemin
HOPS
Protein kinase c like 2
Protein kinase c substrate
80K-H
Homo sapiens glutationes-transferase omega 2
SCAP2
Collagen type 11
Glutamate dehydrogenase
1
Homo sapiens calcium
binding protein Cab 45
precursor
Scaffold Attachment
Factor B
Crystallin, lambda 1
Supressor of Ty 4
homolog
Laminin receptor 1

Omi134-458 OmiCAT134-340 OmiPDZ340-458 L56157-480
+

-

-

+

+

-

+

-

+

-

+

+

+

+

+

+

+
+
+
+

+
+

+
+
+
+

+
+
-

+

+

+

-

+
+
+

+
+
+

+
+
+

+
-

+

+

+

+

+

-

+

-

+
+

+
+

+
+

+
-

+

-

+

-

A positive protein-protein interaction is represented by a +, while no protein-protein interaction
corresponds to a -.
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3.4 Characterization of HOPS

The HOPS protein was isolated twice of the 32 positive clones as a true positive
interactor of LexA-Omi134-458 in the melanocyte library screening. This protein is a novel protein
of unknown function. HOPS is located at chromosome 7q22.3. Using the PSORT II program,
HOPS, the protein is predicted to localize in either the nucleus or mitochondria.

Figure 13: Sequence of HOPS
Nucleotide and amino acid sequence of HOPS. The C-terminal portion underlined in red
represents the clone obtained in the melanocyte library screening.
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A. Genomic structure

HOPS

HOPS

B. Transcript Structure

Figure 14: Genomic Structure of HOPS
(A) The gene is mapped to chromosome 7q22.3. (B) The transcript structure of HOPS. The
gene contains three exons and two introns. Coding sequence is exclusively derived from Exon I.
(Picture taken from:
http://www.ensembl.org/Homo_sapiens/transview?transcript=ENST00000313516&db=core)
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HOPS
GALLUS
MUS
CONSENSUS

HOPS
GALLUS
MUS
CONSENSUS

Figure 15: Alignment of Human HOPS with Mouse and Chicken Orthologues
Gallus: Gallus gallus (novel protein obtained from: www.ensembl.org), Mus: Mus musculus
(NP_080056)
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HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

HOPS
Similar to THAP
CAG12750
putative cytoplasmic protein
consensus

Figure 16: Homology Search
A BLAST search against full length HOPS identifies three other cDNAs with limited homology.
1. HOPS.
2. Similar to THAP domain containing 5 protein [Homo sapiens].
3. Unnamed protein product [Tetraodon nigroviridis].
4. Putative cytoplasmic protein [Salmonella typhimurium LT2].
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Table 3: HOPS Tissue Distribution
Testis
Prostate
Thyroid
Placenta
Colon
Stomach
Aorta
Liver
Cartilage
Head normal
Kidney
Lymph
Muscle (skeletal)
Hippocampus
Medulla
Frontal lobe
White matter
Total fetus
Fetal brain
Embryonic stem cell DMSO treated H9 cell line
Embryonic stem cell treated H1, H7, H9 retina
Embryonic stem cell retinoic acid and mitogenic hES cell line H7
Colon tumor RER
Embryonal carcinoma
Nervous tumor
Parathyroid tumor
Melanotic
melanoma
Retinoblastoma
Acute myelogenous leukemia
Chronic myelogenous leukemia
Moderately differentiated adenocarcinoma
Adenocarcinoma
Hypernephroma cell line
Duodenal adenocarcinoma cell line
Transitional cell papilloma cell line
Mammary adenocarcinoma cell line
Human chondrosarcoma cell line
Mixed
Pooled
2 pooled wilms tumors: one primary and one metastatic to brain
Pooled lung and spleen
2 pooled tumors clear type
Three pooled meningiomas

10.60
1.51
1.51
6.06
1.51
1.51
1.51
3.03
1.51
1.51
3.03
1.51
1.51
1.51
3.03
3.03
1.51
3.03
4.54
1.51
3.03
1.51
1.51
3.03
3.03
1.51
3.03
3.03
1.51
1.51
1.51
1.51
1.51
1.51
1.51
1.51
1.51
1.51
1.51
3.03
1.51
1.51
1.51
1.51

The various tissue distributions of known ESTs for HOPS suggest a wide expression of this
gene. The highest expression is seen in the brain and ectodermally derived organs, as well as
cancer cells.
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3.5 Expression of full-length HOPS protein in Yeast

The full-length cDNA clone of HOPS in the pCMV-SPORT6 vector was obtained (Open
Biosystems I.M.A.G.E. Consortium). PCR was used to prepare DNA corresponding to the
complete coding sequence using the primers described in Materials and Methods. HOPS fulllength cDNA was cloned in frame with the B42 activation domain and HA-tag in the pJG4-5
vector. This prey protein, under the control of a GAL1 promoter, is expressed in yeast only in
the presence of galactose. Whole cell extracts of the transformed yeast grown in either the
presence of glucose or galactose, were subjected to SDS-PAGE.

The expression of this B42

fusion protein was monitored by Western Blot analysis using HA-antibodies (ROCHE). The
HOPS protein can be observed as a band at ≈36 kDa, this corresponds to the estimated molecular
weight of HOPS, ≈26kDa, in fusion with B42 and HA-tag, ≈10kDa.

56

Figure 17: HOPS Expression in Yeast
Expression of HOPS133-233 and full length HOPS protein in the presence of glucose or galactose.
Equal amounts of yeast lysates were subjected to SDS-PAGE followed by Western Blot analysis
using anti-HA primary antibody followed by goat-anti-mouse secondary antibody. Lane 1:
HOPS glucose; Lane 2: HOPS galactose; Lane 3: HOPS133-233 glucose; Lane 4: HOPS133-233
galactose.
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3.6 Interaction of Full-length HOPS Protein With Various Baits in Yeast

The full-length HOPS protein was expressed as a prey in a yeast strain EGY48 along
with one of the following bait proteins: LexA-Omi134-458, LexA-OmiCAT134-340, LexA-OmiPDZ340458,

LexA-L56157-480. The full-length protein interacted with both the mature form of Omi134-458

as well as the OmiPDZ340-458. However, unlike the partial HOPS clone originally isolated from the
melanocyte cDNA library (HOPS137-233) the full length HOPS protein did not interact with

LexA-L56157-480

LexA-OmiPDZ341-458

LexA-OmiCAT134-340

LexA-Omi134-458

L56157-480.

Figure 18: Specificity of the Partial HOPS Clone in Yeast
HOPS137-233 was used as a prey against the following baits: LexA-Omi134-458, LexA-OmiCAT134340, LexA-OmiPDZ340-458, LexA-L56157-480. HOPS137-233 is shown to interact with L56 as well as
Omi, and the PDZ domain of Omi.
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LexA

LexA-L56157-480

LexA-Omi134-458

LexA-OmiCAT134-340

LexA-OmiPDZ341-458

LexA-OmiPDZ341-458
(no prey)

Figure 19: Specificity of the HOPS Clone in Yeast
Yeast colonies were transformed with the indicated bait and the full-length HOPS prey. A blue
colony represents a positive protein-protein interaction, while white colonies indicate no
interaction between bait and prey. HOPS is able to interact with Omi as well as the PDZ domain
of Omi.
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3.7 Degradation Assay

I investigated the possibility that Omi, a serine protease, might be able to degrade HOPS
protein in vitro. [S35]-labeled HOPS was used as a potential substrate against bacterially made
Omi134-458 in an in vitro assay as described (Materials and Methods) Briefly, His-Omi134-458 was
incubated with the [S35]-HOPS in 20µl final reaction volume at 37˚C for 1 hour. The products
were subjected to SDS-PAGE and then observed by autoradiography.
In the presence of Omi134-458, HOPS was cleaved. After degradation, HOPS can
be seen as a band of ≈36kDa and a new peptide band appears between 25kDa and 32kDa (Figure
20).

Figure 20: HOPS is Cleaved by Omi In Vitro
Lane 1: [S35]-HOPS; Lane 2: [S35]-HOPS + His-Omi134-458.
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3.8 Subcellular Localization of HOPS

The full-length HOPS protein was expressed as a fusion to green fluorescent protein
using the pEGFP-C1 (Clontech) mammalian expression vector as described (Materials and
Methods). This construct was co-transfected into HeLa cells with DsRed-Omi134-458. The
pDsRed1-C1 vector (Clontech) fuses a red florescence protein to the C-terminus of Omi. The
HeLa cells were grown on a cover slip and 24 hours after transfection were fixed on the slide so
that the fluorescent proteins could be observed using a confocal microscope. The subcellular
localization of the fluorescent fusion proteins was observed (Figure 21).

A

B

C

D

.
Figure 21: Co-localization of GFP-HOPS137-233 and DsRED-Omi134-458
HeLa cells were transiently co-transfected with both GFP-HOPS137-233 (A) and DsRED-Omi134458 (B). After transfection the cells were fixed and examined by confocal microscopy. Merged
fluorescent images show co-localization of GFP-HOPS and DsRED-Omi (C, D).
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3.9 GFP-HOPS is Cleaved in Mammalian Cells in Response Cisplatin Treatment

293T cells were transfected with pEGFP-HOPS as described in Materials and Methods.
The cells were treated with either H2O2 or Cisplatin for twelve hours. Equal amounts of whole
cell extracts were subjected to SDS-PAGE and the protein level of GFP-HOPS was monitored by
Western blot analysis using anti-GFP monoclonal antibodies, followed by goat-anti-mouse
secondary antibody. GFP-HOPS can be seen as a band at ≈54 kDa, which corresponds to the
estimated molecular weight of HOPS, ≈25kDa, and GFP, ≈29 kDa. In Figure 22, it can be seen
that in the presence of Cisplatin the concentration of HOPS decreases. Equal loading was
monitored using anti-βactin antibodies.
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Figure 22: GFP-HOPS is Degraded in Mammalian Cells after Cisplatin Treatment.
(A) Degradation of GFP-HOPS proteins was monitored by Western Blot analysis. Equal
amounts of whole cell lysates prepared from cells treated with H2O2or Cisplatin were subjected
to SDS-PAGE followed by Western Blot analysis using anti-GFP primary antibody followed by
anti-mouse secondary antibody. Lane 1: GFP-HOPS; Lane 2: GFP-HOPS + H2O2; Lane 3: GFPHOPS + Cisplatin. (B) To verify equal amounts of protein was used in each lane the blot from A
was probed with β-actin antibodies.
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3.10 Expression and Purification of HOPS133-233 in Bacteria

PCR was used to amplify DNA corresponding to HOPS C-terminal (amino acids 137233) domain and cloned into the pET-28A vector as described (Materials and Methods). The
pET28A vector allows proteins to be expressed as fusions with a 6-His-tag. The construct was
then transformed by electroporation into BL21 bacteria. Recombinant protein was purified using
native-state conditions and Ni-NTA beads. The purified recombinant HOPS133-233 protein was
analyzed by SDS-PAGE stained with Coomassie Blue dye. C-terminal HOPS137-233 can be seen
as a band at ≈10kDa, which corresponds to the estimated size (Figure 23).
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Figure 23: Expression and Purification of Recombinant His-HOPS133-233 Protein
His-HOPS133-233 was expressed in BL21 expression strain bacteria. Lane1: Marker; Lane 2:
empty; Lane 3,5, 7, 9: whole cell lysates of BL21containing His-HOPS133-233 not induced; Lane
4, 6, 8, 10: whole cell lysates of BL21 containing His-HOPS133-233 induced with IPTG.
(B) His-HOPS133-233 was purified from BL21 using Ni-NTA beads. Lane 1: Marker; Lane 2 and
Lane 3: BL21 whole cell lysate not induced; Lane 4: BL21 whole cell lysate induced with IPTG;
Lane 5: 5µl purified His-HOPS133-233 elution 2; Lane 6: 10µl purified HOPS elution 2; Lane 7:
15µl purified His-HOPS133-233 elution 2; Lane 8: 15µl purified His-HOPS133-233 elution 1
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3.11 Potential Regulation of Omi’s Proteolytic Activity by Recombinant
HOPS133-233 Protein

The purified His-HOPS133-233 protein was incubated with bacterially made Omi134-458 in
the presence of β-casein, a generic substrate for Omi. The results shown in Figure 24 suggest
that the C-terminus of HOPS133-233 has no regulatory control over Omi’s proteolytic activity
when tested against β-casein.
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Omi134-458
β-casein

HOPS133-233

Figure 24: HOPS133-233 Effect on the Proteolytic Activity of Omi In Vitro
HOPS133-233 does not affect the proteolytic activity of Omi in vitro. His-HOPS133-233 was
incubated with His-Omi134-458 in the presence of β-casein. Lane 1: Marker; Lane 2 β-casein;
Lane 3: β-casein + His-Omi134-458; Lane 4: β-casein + His- Omi134-458 + His-HOPS133-233; Lane 5:
His-Omi134-458 + His-HOPS133-233; Lane 6: His- HOPS133-233.
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3.12 Bacterially Expressed HOPS133-233 is Degraded In Vitro by Omi134-458

The purified His-HOPS133-233 protein was incubated with bacterially made Omi134458

over a time course of 24 hours. Figure 24 shows that even at 4 hours of incubation

HOPS133-233 is degraded.

Omi134-458

HOPS133-233

Figure 25: HOPS133-233 is Degraded by Omi134-458 In Vitro
Lane 1: Molecular Weight marker; Lane 2: His-HOPS133-233 alone; Lane 3: His-Omi134-458+HisOmi134-458 1 hour incubation; Lane 4: His-Omi134-458+His- Omi134-458 2 hour incubation; Lane 5:
His-Omi134-458+His- Omi134-458 3 hour incubation; Lane 6: His-Omi134-458+His- Omi134-458 4 hour
incubation: Lane 7: His-Omi134-458+His- Omi134-458 8 hour incubation; Lane 8: His-Omi134458+His- Omi134-458 24 hour incubation.
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CHAPTER FOUR: DISCUSSION

Omi/HtrA2 is a serine protease belonging to the HtrA family of proteins and is highly
conserved throughout different species.

Omi protein shares homology with the bacterially

expressed heat shock protease HtrA, that functions as a protease at higher temperatures and a
chaperone at lower temperatures (31). Additionally, Omi shares sequence similarity with the
mammalian homologs L56/HtrA1 and PRSP/HtrA3 (31, 34). However, this homology with Omi
lies largely at the carboxy-terminus. Omi possesses a different amino-terminus which contains a
regulatory domain not seen in the other two human homologs (34).
Omi has a series of functional domains including an amino-terminal regulatory domain, a
catalytic domain, and a PDZ domain. The regulatory domain contains a mitochondrial targeting
sequence (MTS), a predicted transmembrane region, a phosphorylation site, and an SH3-binding
domain (28, 33). In the mature form of Omi, the MTS is removed, revealing a conserved IAPbinding motif, AVPS, at the new amino-terminus (29). The conserved catalytic domain has
extensive similarity to serine proteases, such as trypsin, and is involved in the cleavage and
degradation of substrates such as XIAP (35). In accord with other PDZ domains, including those
of the bacterial HtrA, the PDZ domain of Omi is assumed to be involved in protein-protein
interactions (44).
Omi has been identified as an active participant in both the caspase-dependent as well as
caspase-independent pathways of cell death (28, 29, 44). In the caspase-dependent pathway, Omi
binds and degrades IAPs, thus allowing apoptosis to proceed. This is accomplished by two
mechanisms. First, by binding to IAPs through its N-terminal AVPS motif, hindering their
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ability to bind to caspases (46). Secondly, Omi cleaves and irreversibly removes IAPs through
its proteolytic activity (29, 36, 44, 47, 48). Omi is also involved in the caspase-independent
pathway, but the mechanism remains unclear. The proteolytic activity of Omi is necessary and
essential for this “atypical” cell death, and does not involve interaction with IAPs (28, 44).
Recent studies have revealed Omi has yet another unique function in mitochondria (12).
A missense mutation of Omi was identified in Mnd2 mice, which reduces the protease activity of
the protein. This mutation results in a neurodegenerative phenotype rather than the excessive
cell proliferation one would expect if Omi’s sole function were to induce apoptosis. This
suggests that perhaps the primary function of Omi in mammalian cells deals with the
maintenance of mitochondrial homeostasis, and resembling its bacterial homolog, functions as a
chaperone (45).
Omi was first isolated as an interacting protein of Mxi2, an alternatively spliced form of
the p38 stress-activated kinase, using a modified yeast two-hybrid system. The PDZ domain of
Omi specifically recognizes the carboxy-terminus of Mxi2 (31). To date, there are several
known interactors of Omi including the Mxi2, XIAP, cIAP1, the newly identified protein HAX1,
and Presenilin1 (29, 31, 46). XIAP, cIAP and HAX 1 proteins are Omi substrates whose
activation augments cell death. Presenilin1 has recently been shown to boast a different function;
upon interacting with Omi, Presenilin 1 regulates its serine protease activity. A synthetic peptide
encompassing the last 15 carboxy-terminal amino acids of Presenilin 1 is also able to
substantially increase the proteolytic activity of Omi both in vitro as well as in vivo (51).
A screening of a primary melanocyte cDNA library was performed to isolate novel
interacting proteins that may further elucidate the function of Omi. This cDNA library was
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selected under the assumption that, unlike a cancer cell line, primary cells, such as the
melanocytes used here, would have their apoptotic pathway intact and express a range of proapoptotic and anti-apoptotic proteins. Upon screening the cDNA library, a novel protein HOPS
was identified. The isolated partial cDNA of HOPS contained the last 100 amino acids of the
protein. This partial protein was shown to interact with the mature form of Omi, the PDZ
domain of Omi, as well as the mature form of L56 in yeast two hybrid experiments. However,
when the full length HOPS protein was tested in the same assay the results were even more
promising showing that full length HOPS is specific for only Omi and its PDZ domain, and no
longer binds to L56.
Though extensive sequence analysis of HOPS was performed, not much information was
obtained that would suggest a potential function for this protein.

HOPS shares sequence

similarity with only two other proteins. The first is a hypothetical protein from Homo sapiens,
DKFZp564I0422, and second is the protein RIKEN of Mus musculus; each contains only 31%
and 48% sequence similarity, respectively.

Analysis using PSORTII computer software

suggested that the localization of HOPS was either nuclear (39%) or mitochondrial (30%).
However, when transfected in HeLa cells the GFP-HOPS fusion proteins was found
predominantly in the cytoplasm.
HOPS could be involved in the normal function of Omi under two different scenarios. In
the first, HOPS could be a physiological substrate of Omi as is the case with XIAP, cIAP,
HAX1. In the second, like the Presenilin 1, HOPS may regulate the serine protease activity of
Omi. A degradation assay was performed to test the possibility that HOPS might be a substrate
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for the Omi. Mature Omi was incubated with [S35]-HOPS giving rise to one major cleavage
product. This suggested the possibility that HOPS could indeed be a substrate of Omi.
Since the in vitro study revealed the possibility for cleavage, an in vivo experiment was
designed to further confirm these results. GFP-HOPS was transfected in 293T cells and the cells
were then treated with apoptosis-inducing agents including H2O2 and cisplatin. In accord with
the in vitro degradation assay, a decrease in the amount of HOPS protein was observed during
cisplatin-induced apoptosis. These results suggest that HOPS could be a physiological substrate
of Omi that is cleaved and removed during the apoptotic process.
Both Mxi2 and Presenilin 1 have been shown to interact specifically with the PDZ
domain of Omi. PDZ domains are known for their ability to recognize the carboxy- terminus of
proteins. Mxi2 ends in the amino acids LTIYPHLMDIELVMI while Presenilin 1 ends with
VQPFMDQLAFHQFYI. HOPS has sequence homology with both of these proteins as it ends in
the following sequence KIIENHFTTYEVTMI. To ascertain whether or not HOPS alters the
proteolytic activity of Omi, recombinant carboxy-terminal HOPS was purified from bacteria and
used in an enzymatic activity assay. This recombinant HOPS protein encompassed only the last
100 amino acids. When expressed in bacteria, full length HOPS was insoluble, and therefore
could not be purified using non-denaturing conditions.

When the C-terminal HOPS was

incubated with mature Omi in an in vitro assay, no change in the proteolytic activity of the
enzyme was observed. A generic substrate, β-casein, was used in these experiments.
In conclusion, Omi has been shown to interact with a variety of proteins in
mammalian cells. These proteins can be substrates or regulators of Omi’s proteolytic activity.
The isolation of HOPS brings us closer to understanding the mechanism of Omi’s normal
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function. Since the amino acid sequence of HOPS suggests little about its role in the cells, it is
hard to speculate how its degradation and removal by Omi assists the apoptotic process. Further
experiments currently under way in our lab will be used to provide further details on HOPS and
its regulation during cell death.
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